Research Comment englisch - Cardiol Therapeutics Inc. - 13.08.2021
The company portfolio is composed of three therapies in development and one commercial authorization product, Cortalex™, commercialized in late 2020, which is now available across Canada exclusively at Medical Cannabis by Shoppers online portal, part of the largest retail pharmacy chain in Canada. Cortalex’s unique proposition addresses the growing market for high concentration CBD formulations that do not contain THC. Cortalex, which is essentially THC free (<10ppm), is formulated for pediatric and elderly patients, as well as any person who does not wish to be exposed to potential intoxication from THC. Cardiol has recently filed an application for uplisting on the NASDAQ Capital Market and has recently received proceeds of over $10M from the exercise of warrants and stock options. The company has 42.9M shares fully diluted, with 18% insider and employee ownership, and sufficient cash resources to support their research and clinical development programs.
Cardiol Therapeutics Inc. Cardiol Therapeutics Inc is a Canada-based company engaged in the pharmaceutical business sector. The Company is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. It has research programs focused on development of nanotherapeutics to treat heart failure underway. The Company invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.
Die GBC AG mit Sitz in Augsburg ist eines der führenden bankenunabhängigen Investmenthäuser in Deutschland und erfahrener Emissionsexperte für den deutschen Mittelstand.
Die GBC AG kennt als eigentümergeführtes Unternehmen die Bedürfnisse des deutschen Mittelstandes im Finanzierungsbereich und ist ein unabhängiger und verlässlicher Partner bei allen Fragestellungen rund um den Kapitalmarkt.
In der GBC Gruppe bietet die GBC AG Unternehmensanalysen & Research, Kapitalmarkt- & Finanzierungsberatungen sowie Kapitalmarktkonferenzen.
Die GBC Kapital GmbH ergänzt die Leistungen in der Gruppe um das Corporate Finance in den Bereichen Platzierung & Vermittlung von Anleihen und Aktien
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.